New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - colchicine 0.5mg;   - tablet - 0.5 mg - active: colchicine 0.5mg   excipient: lactose monohydrate magnesium stearate maize starch povidone - treatment of acute gout. colchicine should not be used unless nsaids are contraindicated, or have been used and found to lack efficacy or to have unacceptable side effects in the individual patient.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - daunorubicin hydrochloride 2.14 mg/ml equivalent to daunorubicin 2 mg/ml - solution for injection - 2 mg/ml - active: daunorubicin hydrochloride 2.14 mg/ml equivalent to daunorubicin 2 mg/ml excipient: sodium chloride water for injection - daunorubicin injection is indicated for the treatment of the following: · acute lymphocytic (lymphoblastic) leukaemia: daunorubicin is usually reserved for use in cases shown to be resistant to other drugs. however, combined treatment with daunorubicin, vincristine and a steroid has been used in the early stages of this disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - doxorubicin hydrochloride 2 mg/ml;   - concentrate for injection - 2 mg/ml - active: doxorubicin hydrochloride 2 mg/ml   excipient: hydrochloric acid sodium chloride water for injection - doxorubicin has been used successfully to produce regression in neoplastic conditions, e.g. acute leukaemia, wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin's and non-hodgkin's type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas and ovarian carcinoma etc. doxorubicin is also indicated in the primary management of nonmetastatic carcinoma of the bladder (tis, t1, t2) by intravesical administration.

Israel - English - Ministry of Health

rafa laboratories ltd - palonosetron as hydrochloride - solution for injection - palonosetron as hydrochloride 0.25 mg/vial - palonosetron - palonosetron - paloxi is indicated in adults and in paediatric patients 1 month of age and older for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Israel - English - Ministry of Health

rafa laboratories ltd - palonosetron as hydrochloride - solution for injection - palonosetron as hydrochloride 0.25 mg/vial - palonosetron - palonosetron - paloxi is indicated in adults and in paediatric patients 1 month of age and older for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Israel - English - Ministry of Health

abic marketing ltd, israel - methotrexate - solution for injection - methotrexate 25 mg/ml - methotrexate - methotrexate - antineoplastic chemotherapy: treatment of gestational choriocarcinoma, chorioadenoma destruents and hydatidiform mole. palliation of acute lymphocytic leukemia. abitrexate is also indicated in the treatment and prophylaxis of meningeal leukemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukemias in children. in combination with other anticancer agents, abitrexate may be used for the induction of remission, but is most commonly used in maintenance of induced remissions. abitrexate may be used alone or in combination with other antineoplastics in the management of breast cancer, epidermoid cancers of the head and neck, lung cancer (particularly squamous cell and small cell types), bladder cancer and osteogenic cancer. abitrexate is effective in the treatment of the advanced stages (iii and iv peter's staging system) of lymphosarcoma, particularly in children, and in advanced cases of mycosis fungoides. psoriasis: because of the high risk attending its use, abitrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: abitrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.

Israel - English - Ministry of Health

abic marketing ltd, israel - vincristine sulfate - solution for injection - vincristine sulfate 1 mg/ml - vincristine - vincristine - vincristine may be used either as sole agent or in combination therapy in the treatment of acute leukemias. malignant lymphomas including hodgkin's disease lymphosarcoma and reticulum cell sarcoma, neuroblastoma, wilm's tumor, rhabdomyosarcoma.

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - doxorubicin hydrochloride - concentrate for soln for inf - 2 mg/ml - doxorubicin

Ireland - English - HPRA (Health Products Regulatory Authority)

strides arcolab international limited - epirubicin hydrochloride - solution for inj/inf - 2 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi oncology plc - epirubicin hydrochloride - solution for inj/inf - 2 micromol - anthracyclines and related substances